|
US5169761A
|
|
Dna encoding and expression systems for alveolar surfactant proteins
|
|
WO9104339A1
|
|
Assays and reagents for amyloid deposition
|
|
CA2063273A1
|
|
Surfactant compositions and methods
|
|
US5104853A
|
|
Alveolar surfactant proteins having cys to ser mutations
|
|
IE901593L
|
|
Basic fibroblast growth factor
|
|
US5136025A
|
|
Method to purify basic fibroblast growth factor
|
|
US5143829A
|
|
High level expression of basic fibroblast growth factor having a homogeneous n-terminus
|
|
US5194596A
|
|
Production of vascular endothelial cell growth factor
|
|
IE892647L
|
|
Atrial natriuretic peptide clearance inhibitors
|
|
IE892600L
|
|
Stabilizing heterologous protein expression
|
|
EP0429537A1
|
|
Atrial natriuretic peptide clearance inhibitors
|
|
AU4216689A
|
|
Method for stabilizing heterologous protein expression and vectors for use therein
|
|
US5114923A
|
|
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
|
CA1339210C
|
|
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
|
US5130418A
|
|
Method to stabilize basic fibroblast growth factor
|
|
US5011678A
|
|
Composition and method for administration of pharmaceutically active substances
|
|
US4994439A
|
|
Transmembrane formulations for drug administration
|
|
ZA8809598B
|
|
Linear analogs of atrial natriuretic peptides
|
|
AU2927889A
|
|
Linear analogs of atrial natriuretic peptides
|
|
US5047397A
|
|
Linear analogs of atrial natriuretic peptides
|
